-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$16.67106.57% Upside
Theravance Biopharma, Inc. Frequently Asked Questions
-
What analysts cover Theravance Biopharma, Inc.?
Theravance Biopharma, Inc. has been rated by research analysts at H.C. Wainwright, BTIG, Leerink Partners in the past 90 days.